The U.S. Food and Drug Administration (FDA) has cleared the start of clinical testing of FT839, Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans to launch a basket Phase 1/2 clinical trial to evaluate FT839 in combination with…
News
Blood cell ratios derived from routine blood tests may help distinguish people with active ANCA-associated vasculitis (AAV) from those in glucocorticoid-free remission, independent of age and sex, according to a new study. “Our findings suggested that these readily available, standardized, low-cost biomarkers make them attractive candidates for integration into…
Black people with ANCA-associated vasculitis (AAV) were diagnosed at a younger age than white people and tended to show more signs of kidney disease severity, according to a study in the U.S. “These findings suggest that [variability] in disease presentation within the spectrum of AAV highlights the importance of examining…
Following regulatory attempts in Europe to revoke approval of its ANCA-associated vasculitis (AAV) therapy Tavneos (avacopan), developer Inflarx is now looking to advance two new treatments — both being tested in clinical trials — for this group of autoimmune diseases. The biopharmaceutical company said in a…
A committee of the European Medicines Agency has recommended revoking the marketing authorization for Tavneos (avacopan) — an approved oral therapy for ANCA-associated vasculitis (AAV) — in the European Union (EU) over questions about the drug’s effectiveness data. The recommendation, from the Committee for Medicinal Products for…
People with eosinophilic granulomatosis with polyangiitis (EGPA) waited a median of nearly four years from their first recorded major sign of the disease to diagnosis, and most received prescriptions for oral glucocorticoids and/or immunosuppressants, a real-world study in England shows. Also, in a 486-patient group followed from diagnosis, more…
Nearly half of ANCA-associated vasculitis (AAV) patients treated with rituximab developed hypogammaglobulinemia (HGG), or low blood levels of antibodies, according to a population-based Swedish study. While antibodies normally help fight infections, the occurrence of HGG was not associated with an increased risk of severe infections among rituximab-treated patients…
The ANCA-associated vasculitis Patient-Reported Outcome (AAV-PRO) questionnaire captures physical, social, emotional, and symptom-related burdens that are closely linked to difficulties in daily life but are not always reflected in physician assessments. That’s according to a study in Germany that used the German-language version of the AAV-PRO questionnaire, which had…
Measuring urine levels of two proteins in people with ANCA-associated vasculitis (AAV) and kidney involvement independently predicted their risk of progression to kidney failure, according to a new study from China. The researchers found that noninvasive testing of trehalase and neutrophil gelatinase-associated lipocalin (NGAL), two highly sensitive urinary biomarkers,…
Certain T-cells may show excessive activity in a signaling pathway called STAT3-PIM1 in people with granulomatosis with polyangiitis (GPA) who test positive for antibodies against proteinase 3 (PR3-GPA), according to a new study. Researchers aimed to identify unique activity patterns in T-cells containing the CD4 protein marker (CD4+ T-cells),…
Recent Posts
- FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions
- It’s OK to feel frustrated by the unpredictability of life with vasculitis
- Routine blood tests may help doctors track AAV activity, study finds
- New study points to racial differences in AAV age and kidney severity
- What you should know about AAV and service-connected disability